SEC Comment Letter 0000000000-24-002751 to Aldeyra Therapeutics, Inc. (ALDX) (CIK 0001341235) (ALDX)
Aldeyra Therapeutics, Inc. (ALDX) (CIK 0001341235)
Date: March 13, 2024 · CIK: 0001341235 · Accession: 0000000000-24-002751
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-277753
Letter
United States securities and exchange commission logo March 13, 2024 Todd Brady Chief Executive Officer Aldeyra Therapeutics, Inc. 131 Hartwell Avenue, Suite 320 Lexington, MA 02421 Re:Aldeyra Therapeutics, Inc. Registration Statement on Form S-3 Filed March 7, 2024 File No. 333-277753 Dear Todd Brady: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Doris Stacey Gama at 202-551-3188 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Keith J. Scherer, Esq.
Show Raw Text
United States securities and exchange commission logo
March 13, 2024
Todd Brady
Chief Executive Officer
Aldeyra Therapeutics, Inc.
131 Hartwell Avenue, Suite 320
Lexington, MA 02421
Re:Aldeyra Therapeutics, Inc.
Registration Statement on Form S-3
Filed March 7, 2024
File No. 333-277753
Dear Todd Brady:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Doris Stacey Gama at 202-551-3188 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Keith J. Scherer, Esq.